CLAIMS

1- Use of Nanoparticules comprising at least one chemotherapeutic antitumoral agent, at least one poly(alkylcyanoacrylate) and at least one cyclodextrin, ~~for use~~ for the manufacture of a medicament for use in treating a cancer, wherein the Nanoparticules are administered by intravenous or intra-arterial infusion for at least 2 hours.

2- The use ~~Nanoparticules~~ according to claim 1, wherein the Nanoparticules are to be administered by intravenous or intra-arterial infusion for between 2 and 24 hours.

3- The use ~~Nanoparticules~~ according to claim 1 or 2, wherein the Nanoparticules are to be administered by intravenous or intra-arterial infusion for between 4 and 12 hours.

4- The use ~~Nanoparticules~~ according to any one of claims 1 to 3, wherein the Nanoparticules are to be administered by intravenous or intra-arterial infusion for about 6 hours.

5- The use ~~Nanoparticules~~ according to any one of claims 1 to 4, wherein said at least one poly(alkylcyanoacrylate) is a polyisohexylcyanoacrylate.

6- The use ~~Nanoparticules~~ according to any one of claims 1 to 5, wherein the Nanoparticules comprise said at least one chemotherapeutic agent at a concentration from 0.01 to 200 mg/g of Nanoparticules, from 0.1 to 70 % w/w of said at least one cyclodextrin and from 1 to 25 % w/w of said at least one poly(alkylcyanoacrylate).

7- The use ~~Nanoparticules~~ according to any one of claims 1 to 6, wherein said at least one chemotherapeutic antitumoral agent is selected from the group consisting of anthracyclines, topoisomerase I and/or II inhibitors, spindle poison plant alkaloids, alkylating agents, anti-metabolites, ellipticine and harmine, and any combination thereof.

8. The use ~~Nanoparticules~~ according to claim 7, wherein said at least one chemotherapeutic antitumoral agent is an anthracycline, preferably selected from the group

consisting of doxorubicin, daunorubicin, epirubicin, idarubicin, valrubicin, pirarubicin, zorubicin, aclarubicin, detorubicin, carminomycin, morpholinodoxorubicin, morpholinodaunorubicin, methoxymorpholinyldoxorubicin, any pharmaceutically acceptable salt thereof, and any combination thereof.

9- The use ~~Nanoparticules~~ according to claim 8, wherein said at least one chemotherapeutic antitumoral agent is doxorubicin or any pharmaceutically acceptable salt thereof.

10- The use ~~Nanoparticules~~ according to claim 9, wherein the dosage of doxorubicin is from about 10 to about 75 mg/m^2.

11- The use ~~Nanoparticules~~ according to claim 9 or 10, wherein the dosage of doxorubicin is from about 10 to about 45 mg/m^2.

12- The use ~~Nanoparticules~~ according to any one of claims 9 to 11, wherein the dosage of doxorubicin is from about 10 to about 30 mg/m^2.

13- The use ~~Nanoparticules~~ according to any one of claims 9 to 12, wherein the dosage of doxorubicin is about 20 to about 30 mg/m^2.

14- The use ~~Nanoparticules~~ according to any one of claims 1 to 13, wherein the cancer is a solid tumor or a hematopoietic tumor, preferably selected from the group consisting of hepatocellular carcinoma, acute lymphoblastic leukemia, acute myeloblastic leukemia, chronic myelogenous leukemia, Hodgkin's disease, diffuse large B-cell lymphoma, small cell lung cancer, colorectal cancer, pancreas cancer, breast cancer, ovary cancer, uterine cancer, cervix cancer, head and neck cancer, brain cancer, blade cancer, multiple myeloma, neuroblastoma, Edwing's sarcoma, osteosarcoma, soft tissue sarcoma, thyroid cancer, prostate cancer, stomach cancer, nephroblastoma, Kaposi's sarcoma, and non-Hodgkins lymphoma.

15- The use ~~Nanoparticules~~ according to any one of claims 1 to 14, wherein the cancer is a hepatocellular carcinoma.